

No. 22-671

IN THE
Supreme Court of the United States

NOVARTIS PHARMACEUTICALS CORPORATION,

Petitioner,

v.

HEC PHARM CO., LTD., HEC PHARM USA INC.,

Respondents.

**On Petition for a Writ of Certiorari to the
United States Court of Appeals
for the Federal Circuit**

**BRIEF OF *AMICI CURIAE*
INTELLECTUAL PROPERTY PROFESSORS
IN SUPPORT OF PETITIONER**

DOMINICK A. CONDE

Counsel of Record

CHRISTOPHER E. LOH

VENABLE LLP

1290 Avenue of the Americas

New York, NY 10104

(212) 218-2204

dconde@venable.com

Counsel for Amici Curiae

February 21, 2023

WILSON-EPES PRINTING CO., INC. – (202) 789-0096 – WASHINGTON, D.C. 20002

TABLE OF CONTENTS

	Page
TABLE OF AUTHORITIES.....	ii
INTEREST OF <i>AMICI CURIAE</i>	1
INTRODUCTION AND SUMMARY OF ARGUMENT	1
ARGUMENT.....	2
I. The New Written Description Standard Conflicts with Supreme Court and Federal Circuit Precedent	2
II. The New Written Description Standard Deprives Patentees of the Ability to Limit Claims to Avoid the Prior Art	6
III. The Second Federal Circuit Panel Engaged in Improper Fact-Finding	9
CONCLUSION	13
APPENDIX:	
LIST OF SIGNATORIES	1a

TABLE OF AUTHORITIES

CASES	Page(s)
<i>Allergan, Inc. v. Sandoz Inc.</i> , 796 F.3d 1293 (Fed. Cir. 2015).....	10
<i>Apotex Inc. v. Novartis AG</i> , IPR2017-00854, 2018 WL 3414289 (P.T.A.B. July 11, 2018).....	12
<i>Ariad Pharms., Inc. v. Eli Lilly & Co.</i> , 598 F.3d 1336 (Fed. Cir. 2010).....	4, 10, 11
<i>Bell & Howell Document Mgmt. Prods. Co.</i> <i>v. Altek Sys.</i> , 132 F.3d 701 (Fed. Cir. 1997).....	10
<i>Capon v. Eshhar</i> , 418 F.3d 1349 (Fed. Cir. 2005).....	10-12
<i>Falkner v. Inglis</i> , 448 F.3d 1357 (Fed. Cir. 2006).....	12
<i>Gentry Gallery, Inc. v. Berkline Corp.</i> , 134 F.3d 1473 (Fed. Cir. 1998).....	12
<i>Halo Elecs., Inc. v. Pulse Elecs., Inc.</i> , 579 U.S. 93 (2016).....	5
<i>Hybritech, Inc. v. Monoclonal Antibodies, Inc.</i> , 802 F.2d 1367 (Fed. Cir. 1986).....	11
<i>In re Johnson</i> , 558 F.2d 1008 (C.C.P.A. 1977).....	7
<i>In re Saunders</i> , 444 F.2d 599 (C.C.P.A. 1971).....	7
<i>In re Wertheim</i> , 541 F.2d 257 (C.C.P.A. 1976).....	6, 7

TABLE OF AUTHORITIES—Continued

	Page(s)
<i>Inphi Corp. v. Netlist, Inc.</i> , 805 F.3d 1350 (Fed. Cir. 2015).....	4
<i>KSR Int’l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	5
<i>Microsoft Corp. v. I4I Ltd. Partnership</i> , 564 U.S. 91 (2011).....	3-4
<i>Octane Fitness, LLC v. ICON Health & Fitness, Inc.</i> , 572 U.S. 545 (2014).....	5
<i>Pozen Inc. v. Par Pharm., Inc.</i> , 696 F.3d 1151 (Fed. Cir. 2012).....	5
<i>Pozen Inc. v. Par Pharm., Inc.</i> , 800 F. Supp. 2d 789 (E.D. Tex. 2011).....	5
<i>Smith v. Snow</i> , 294 U.S. 1 (1935).....	4
<i>Streck, Inc. v. Research & Diagnostic Sys., Inc.</i> , 665 F.3d 1269 (Fed. Cir. 2012).....	12
<i>Tech. Licensing Corp. v. Videotek, Inc.</i> , 545 F.3d 1316 (Fed. Cir. 2008).....	4
<i>Teva Pharms. USA, Inc. v. Sandoz, Inc.</i> , 574 U.S. 318 (2015).....	9
<i>Tronzo v. Biomet, Inc.</i> , 156 F.3d 1154 (Fed. Cir. 1998).....	4
<i>Union Oil Co. of Cal. v. Atl. Richfield Co.</i> , 208 F.3d 989 (Fed. Cir. 2000).....	7, 12
 STATUTES	
35 U.S.C. § 103	5

TABLE OF AUTHORITIES—Continued

	Page(s)
35 U.S.C. § 284	5
35 U.S.C. § 285	5
RULES	
Fed. R. Civ. P. 52(a)(6)	2, 9
OTHER AUTHORITIES	
Andrew Karpan, <i>Fed. Circ. Reverses Initial Panel To Find Gilenya IP Invalid</i> , Law 360, June 21, 2022	11
D. Karshedt <i>et al.</i> , <i>The Death of the Genus Claim</i> , 35 Harv. J.L. & Tech. 1 (2021).....	8
J.A. DiMasi <i>et al.</i> , <i>Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs</i> , 47 J. Health Econ. 20 (2016).....	8-9
John Carroll, <i>One Drug, Many Uses</i> , 2 Biotechnol. Healthc. 56 (2005)	8
Jorge Mestre-Ferrandiz <i>et al.</i> , <i>The R&D Cost of a New Medicine</i> , Off. Health Econ. (2012).....	9
Kaitlin Farrell and Austin Keith, <i>Federal Circuit Rehearing Panel Vacates its January Decision and Reverses District Court Finding of Sufficient Written Description for Negative Claim Limitation</i> , J.D. Supra, July 6, 2022.....	11

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.